In the News
Statement from Global Alzheimer’s Platform (GAP) Foundation in Response to Bill Gates’ Investment in Alzheimer’s Research
WASHINGTON, D.C. – “The Global Alzheimer’s Platform Foundation (GAP) enthusiastically welcomes Bill Gates and his team to the fight against Alzheimer’s disease. This epidemic, which affects millions of people worldwide, is growing exponentially and requires new thinking and investment to begin to stem that tide. We at Global Alzheimer’s Platform Foundation are focused on disrupting the Alzheimer’s clinical trial […]
Read more »Can GAP double the number of patients in Alzheimer’s trials?
Curing diseases requires new drugs. Getting those new drugs approved by regulators requires data from successful clinical trials. Those trials depend on patients, and right now getting those patients is a challenge for many sponsor companies. According to research performed on recruitment, 85 percent of trials are delayed due to enrollment issues and more than […]
Read more »Minority Participation in Clinical Trials can Help Everyone Fight Alzheimer’s
Growing up as an African-American in the South over 75 years ago, my family didn’t have the access to medical care we do today. One event from my childhood changed my life. My mother went to the doctor’s office. She was quite ill and needed help. The doctor said she had to wait to be […]
Read more »Global Alzheimer’s Platform (GAP) Foundation Unites 58 of the World’s Leading Research Sites With Goal of Doubling Clinical Trial Participation in USA
More than Half of All National Clinical Trials in Alzheimer’s Take Place at GAP Networked Sites Kansas City Pilot Program Increased Volunteer Trial Participation by 292% WASHINGTON, D.C. (November 1, 2017) – Alzheimer’s disease affects more than 5.4 million Americans and costs taxpayers at least $153 billion dollars per year in Medicare and Medicaid expenses alone. […]
Read more »Patient Advocacy Groups Welcome 40% Increase in Alzheimer’s NIH Research Funds Authorized by Congress
The U.S. Congress last week authorized an additional 40 percent in funds for Alzheimer’s disease (AD) research, boosting the fiscal 2017 total by $400 million to nearly $1.4 billion as part of a $2 billion year-over-year increase for the National Institutes of Health (NIH). The final package won praise from the nonprofit Global Alzheimer’s Platform Foundation (GAP), […]
Read more »Global Alzheimer’s Platform Foundation Supports $400 Million Congressional Increase for Alzheimer’s Research Funding
Increase is Part of National Institutes of Health (NIH) $2 Billion Funding Boost Bipartisan Support is Good Newsfor 5.5 Million Americans Living with Alzheimer’s and their Caregivers WASHINGTON, D.C. (May 4, 2017) – The Global Alzheimer’s Platform Foundation, a nonprofit organization dedicated to expediting Alzheimer’s clinical trials, applauds today’s $400 million Congressional increase in Alzheimer’s research funding. Under the bipartisan vote, the National […]
Read more »Hope to Prevent Alzheimer’s? Grab the Olive Oil and Hop on a Treadmill
Ann Poehler’s strides quicken on the treadmill. Her feet pound. Her heart races from 150 to 160 beats per minute and more. A plastic tube jutting from the Prairie Village woman’s mouth feeds carbon dioxide levels to a computer here inside the University of Kansas Alzheimer’s Disease Center. The computer records every respiration while an exercise […]
Read more »Global Alzheimer’s Platform Foundation Appoints Pascale Witz to Board of Directors
Pascale Witz brings two decades of healthcare leadership experience to GAP Board WASHINGTON, D.C. (Sep. 15, 2016) – Global Alzheimer’s Platform Foundation, Inc. (GAP), a nonprofit organization dedicated to reducing the duration, cost and risk of Alzheimer’s clinical trials, today announced the appointment of Pascale Witz to its Board of Directors. In this role, Pascale will provide counsel based […]
Read more »National Survey Finds that a Majority of Americans Would Consider Participating in an Alzheimer’s Clinical Trial
A recent online survey conducted by Harris Poll found that nearly 60% of Americans are definitely willing or willing to consider taking part in a clinical trial for Alzheimer’s. This promising statistic is good news for researchers; however, obtaining qualified trial participants has been one of the greatest challenges in getting clinical trials off the […]
Read more »Global Alzheimer’s Platform Foundation Announces GAP-Net
First?of?its?Kind Network of Clinical Trial Sites Quickens Timeline and Quality of Alzheimer’s Clinical Trials WASHINGTON, D.C. (July 28, 2016) – The Global Alzheimer’s Platform Foundation (GAP) announced the launch of GAP?Net, a first?of?its?kind network of clinical trial sites collaboratively working to streamline clinical research and drug development for Alzheimer’s disease. GAP?Net currently has 11 leading academic and private commercial […]
Read more »Global Alzheimer’s Platform Foundation Appoints Dr. Kate Zhong as Chief Strategy Officer
Dr. Zhong Brings More Than 20 Years of Experience to Organization’s New Role WASHINGTON, D.C. (July 27, 2016) – Global Alzheimer’s Platform Foundation (GAP), a nonprofit organization dedicated to reducing the time, cost and risk of Alzheimer’s clinical trials, today announced the appointment of Dr. Kate Zhong to the new position of Chief Strategy Officer (CSO). In this […]
Read more »Majority Of Americans Would Consider Participating In An Alzheimer’s Clinical Trial. So, Why Are Enrollment Numbers So Low?
Global Alzheimer’s Platform (GAP) Foundation is promoting innovative and easier?to?use clinical trial participation tools, including the Brain Health Registry WASHINGTON, D.C. (July 18, 2016) – In a first?ever poll conducted online by Harris Poll on behalf of the Global Alzheimer’s Platform (GAP) Foundation, nearly 60% of Americans report they are definitely willing or would consider participating […]
Read more »